Cargando…
Rituximab reduces anti-cardiolipin levels in patients with systemic lupus erythematosus
Autores principales: | Martínez-Pérez, R, Muñoz-Jiménez, A, Rodríguez-Montero, S, Fernández-Nebro, A, Carreño, L, Marenco, J L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007816/ http://dx.doi.org/10.1186/1479-5876-8-S1-P69 |
Ejemplares similares
-
Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010) -
Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy
por: Martínez, R, et al.
Publicado: (2010) -
Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
por: Alves, Alessandra, et al.
Publicado: (2014) -
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
por: Muñoz, A, et al.
Publicado: (2010) -
An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
por: Eisenberg, RA, et al.
Publicado: (2004)